{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T16:57:35Z","timestamp":1789232255066,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.neurot.2025.e00558","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T07:30:14Z","timestamp":1740641414000},"page":"e00558","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L)"],"prefix":"10.1016","volume":"22","author":[{"given":"Sarah E.","family":"Conway","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Galetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00558_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"key":"10.1016\/j.neurot.2025.e00558_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.neurot.2025.e00558_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.neurot.2025.e00558_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.neurot.2025.e00558_bib5","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1212\/WNL.0000000000012122","article-title":"Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: a systematic review","volume":"97","author":"Nersesjan","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00558_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2016-209782","article-title":"Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases","volume":"76","author":"Calabrese","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.neurot.2025.e00558_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.neurot.2025.e00558_bib8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11910-023-01306-x","article-title":"Immune checkpoint inhibitors in patients with pre-existing neurologic autoimmune disorders","volume":"23","author":"Aoun","year":"2023","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.neurot.2025.e00558_bib9","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1007\/s00415-019-09562-z","article-title":"Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer","volume":"266","author":"Romeo","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00558_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ana.24715","article-title":"CTLA4 as immunological checkpoint in the development of multiple sclerosis","volume":"80","author":"Gerdes","year":"2016","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00558_bib11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1177\/1352458514549403","article-title":"Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma","volume":"21","author":"Gettings","year":"2015","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00558_bib12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/13524585221117949","article-title":"Neurologic disease activity in people with multiple sclerosis treated with immune checkpoint inhibitors","volume":"29","author":"Conway","year":"2023","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00558_bib13","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200202","article-title":"Impact of immune checkpoint inhibitors on the course of multiple sclerosis","volume":"11","author":"Androdias","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurot.2025.e00558_bib14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","article-title":"High-efficacy therapy discontinuation vs continuation in patients 50 Years and older with nonactive MS","volume":"81","author":"Jouvenot","year":"2024","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00558_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105134","article-title":"Frequency and risk factors of rebound after fingolimod discontinuation - a retrospective study","volume":"81","author":"Maunula","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00558_bib16","article-title":"Clinical outcomes after use of checkpoint inhibitor immunotherapies in people with multiple sclerosis","volume":"10","author":"Nylander","year":"2024","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.neurot.2025.e00558_bib17","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.1007\/s00415-023-11933-6","article-title":"Frequency of demyelinating disease activity following immune checkpoint inhibitor cancer immunotherapy","volume":"270","author":"Hasan","year":"2023","journal-title":"J Neurol"},{"key":"10.1016\/j.neurot.2025.e00558_bib18","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210003","article-title":"Neurologic outcomes in people with multiple sclerosis treated with immune checkpoint inhibitors for oncologic indications","volume":"103","author":"Quinn","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00558_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16547","article-title":"Do immune checkpoint inhibitors affect the course of multiple sclerosis? A systematic review and meta-analysis","volume":"32","author":"Gelibter","year":"2025","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurot.2025.e00558_bib20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awac237","article-title":"Progressive multifocal leukoencephalopathy: epidemiology and spectrum of predisposing conditions","volume":"146","author":"Joly","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00558_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1086\/520514","article-title":"Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera","volume":"196","author":"Verma","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.neurot.2025.e00558_bib22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1136\/jnnp.2006.092353","article-title":"Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis","volume":"77","author":"Vulliemoz","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurot.2025.e00558_bib23","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00558_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.26512","article-title":"Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors","volume":"93","author":"Boumaza","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00558_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25927","article-title":"Role of B Cells in multiple sclerosis and related disorders","volume":"89","author":"Comi","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00558_bib26","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.neurot.2025.e00558_bib27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.neurot.2025.e00558_bib28","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00558_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.neurot.2025.e00558_bib30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.neurot.2025.e00558_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.neurot.2025.e00558_bib32","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total costs of chimeric antigen receptor T-cell immunotherapy","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.neurot.2025.e00558_bib33","first-page":"550","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"M\u00e9dica Sur"},{"key":"10.1016\/j.neurot.2025.e00558_bib35","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3389\/fimmu.2017.01791","article-title":"The CD40-cd40l dyad in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"8","author":"Aarts","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.neurot.2025.e00558_bib36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.smim.2009.05.012","article-title":"CD40 and autoimmunity: the dark side of a great activator","volume":"21","author":"Peters","year":"2009","journal-title":"Semin Immunol"},{"key":"10.1016\/j.neurot.2025.e00558_bib37","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1073\/pnas.93.6.2499","article-title":"CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis","volume":"93","author":"Gerritse","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2025.e00558_bib38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1468-1331.2001.00232.x","article-title":"Increased T cell expression of CD154 (CD40-ligand) in multiple sclerosis","volume":"8","author":"Jensen","year":"2001","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurot.2025.e00558_bib39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneuroim.2017.01.024","article-title":"Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"305","author":"Masuda","year":"2017","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurot.2025.e00558_bib40","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1073\/pnas.1231363100","article-title":"CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation","volume":"100","author":"Imadome","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neurot.2025.e00558_bib41","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.neurot.2025.e00558_bib42","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001096","article-title":"Safety and immune effects of blocking CD40 ligand in multiple sclerosis","volume":"8","author":"Fadul","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.neurot.2025.e00558_bib43","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2309439","article-title":"Inhibition of CD40L with frexalimab in multiple sclerosis","volume":"390","author":"Vermersch","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:03:16Z","timestamp":1755090196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1878747925000364"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00558","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L)","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00558","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00558"}}